Clear ×
Arbutus Biopharma Corp ABUS

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Oct 22, 2026 8-K 4 signals fired
Core
Clinical Hold Lead Asset Progress Indication Expansion
Biotech Risk
Clinical Hold Active
Aug 21, 2026 8-K 5 signals fired
Core
Indication Expansion Lead Asset Progress
Other
Share Repurchase Activity Disclosed Merger Proxy Statement Disclosure Tender Offer Withdrawal Disclosure
Aug 12, 2026 10-Q 42 signals fired · top 15
Other
Rsu Psu Vesting Schedule Disclosed Clawback Policy Disclosed Liquidity Position Snapshot Disclosed Restructuring Charge Disclosed Share Withholding Tax Settlement Checkpoint Inhibitor Program Nqso Definition Provision Protocol Amended Equity Plan Participant Data Authorization Shares Outstanding Disclosure Section 409A Compliance Statement Cash Flow Statement Investing Activities Interim Data Positive Quarterly Dividend Declared
Core
Clinical Trial Result
Jul 16, 2026 8-K 0 signals fired
No signals above threshold for this filing.
May 27, 2026 8-K 17 signals fired · top 15
Other
Equity Plan Board Approval Conditional On Shareholder Vote Auditor Appointment Ratification Committee Discretionary Authority Clause Market Price Definition Performance Unit Award Establishment Equity Award Plan Types Enumerated Nqso Definition Provision Section 409A Compliance Statement Transfer And Demand Rights Limitations Equity Award Non Transferability Clause Ltip Plan Title Citation Nyse Listing Disclosure Stock Option Ten Year Expiration Term Plan Committee Administration Clause Equity Plan Amendment Restriction
May 13, 2026 10-Q 26 signals fired · top 15
Other
Liquidity Position Snapshot Disclosed Fast Track Designation Received Fast Track Granted Orphan Status Granted Restructuring Charge Disclosed Capital Raising Uncertainty Disclosed Cash Flow Statement Investing Activities Shares Outstanding Disclosure Patient Retention High Workforce Reduction Restructuring Plan
Core
Regulatory Designation Only Clinical Trial Result Indication Expansion
Biotech Risk
Orphan Drug Designation
Healthcare
Utilization Declining Services